BACKGROUND: Biologic aggressiveness of head and neck carcinoma is reflected in its capability to metastasize to regional lymph nodes and its propensity to recur after treatment. METHODS: The authors report on 244 patients treated at the Department of Otolaryngology-Head and Neck Surgery of the Free University Hospital, Amsterdam, The Netherlands, with excision of primary tumor with incontinuity neck dissection with or without postoperative radiation therapy between January 1973 and July 1986. All patients had surgical margins free of tumor. RESULTS: The overall recurrence rate was 12.3%. Stages T3-4 and the presence of more than three positive nodes on histopathologic examination were associated with a 16.2% and 26.2% incidence in recurrence at the primary site, respectively. No prognostic influence arose from primary tumor localization, three or fewer positive nodes, extranodal spread, and postoperative radiation therapy. CONCLUSIONS: Patients with T3-4 disease and those with more than three positive lymph nodes may benefit from novel adjuvant treatment modalities.
BACKGROUND: Biologic aggressiveness of head and neck carcinoma is reflected in its capability to metastasize to regional lymph nodes and its propensity to recur after treatment. METHODS: The authors report on 244 patients treated at the Department of Otolaryngology-Head and Neck Surgery of the Free University Hospital, Amsterdam, The Netherlands, with excision of primary tumor with incontinuity neck dissection with or without postoperative radiation therapy between January 1973 and July 1986. All patients had surgical margins free of tumor. RESULTS: The overall recurrence rate was 12.3%. Stages T3-4 and the presence of more than three positive nodes on histopathologic examination were associated with a 16.2% and 26.2% incidence in recurrence at the primary site, respectively. No prognostic influence arose from primary tumor localization, three or fewer positive nodes, extranodal spread, and postoperative radiation therapy. CONCLUSIONS:Patients with T3-4 disease and those with more than three positive lymph nodes may benefit from novel adjuvant treatment modalities.
Authors: S C Loke; A Karandikar; M Ravanelli; D Farina; J P N Goh; E A Ling; R Maroldi; T Y Tan Journal: Neuroradiology Date: 2015-09-30 Impact factor: 2.804
Authors: R B J de Bondt; M C Hoeberigs; P J Nelemans; W M L L G Deserno; C Peutz-Kootstra; B Kremer; R G H Beets-Tan Journal: Neuroradiology Date: 2009-01-10 Impact factor: 2.804
Authors: Lei Huang; Odile David; Robert J Cabay; Klara Valyi-Nagy; Virgilia Macias; Rong Zhong; Barry Wenig; Lawrence Feldman; Ralph Weichselbaum; Michael T Spiotto Journal: Clin Cancer Res Date: 2018-12-20 Impact factor: 12.531
Authors: Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2014-02-27 Impact factor: 7.396